An improved method for the simultaneous determination of losartan and its major metabolite, EXP3174, in human plasma and urine by high-performance liquid chromatography with fluorescence detection

J Pharm Biomed Anal. 1997 Apr;15(7):1021-9. doi: 10.1016/s0731-7085(96)01948-6.

Authors

M A Ritter¹, C I Furtek, M W Lo

Affiliation

¹ Department of Drug Metabolism, Merck Research Laboratories, West Point, PA 19486, USA.

PMID: 9160270
DOI: 10.1016/s0731-7085(96)01948-6

No abstract available

MeSH terms

Angiotensin Receptor Antagonists*
Antihypertensive Agents / analysis*
Antihypertensive Agents / blood
Antihypertensive Agents / urine
Biphenyl Compounds / analysis*
Biphenyl Compounds / blood
Biphenyl Compounds / urine
Chromatography, High Pressure Liquid
Humans
Imidazoles / analysis*
Imidazoles / blood
Imidazoles / urine
Losartan
Receptor, Angiotensin, Type 1
Receptor, Angiotensin, Type 2
Reproducibility of Results
Sensitivity and Specificity
Spectrometry, Fluorescence
Tetrazoles / analysis*
Tetrazoles / blood
Tetrazoles / urine

Substances

Angiotensin Receptor Antagonists
Antihypertensive Agents
Biphenyl Compounds
Imidazoles
Receptor, Angiotensin, Type 1
Receptor, Angiotensin, Type 2
Tetrazoles
losartan carboxylic acid
Losartan